Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

3081 - Optimal interval from preceding radiotherapy (RT) to enhance efficacy of immune check point inhibitors (ICIs): consecutive analysis of 294 patients with non-small cell lung cancer (NSCLC)


20 Oct 2018


Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research


Hidehito Horinouchi


Annals of Oncology (2018) 29 (suppl_8): viii493-viii547. 10.1093/annonc/mdy292


H. Horinouchi1, Y. Matsumoto1, S. Murakami1, Y. Goto1, S. Kanda1, Y. Fujiwara1, N. Yamamoto1, Y. Nakayama2, Y. Ohe1

Author affiliations

  • 1 Department Of Thoracic Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 2 Department Of Radiation oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3081


Based on the preclinical findings, preceding RT enhances efficacy of ICIs. Phase III trial (PACIFIC) evaluating efficacy of durvalumab as consolidation after chemo-RT showed significant improvement in progression-free survival (PFS) in patients with stage III NSCLC (Antonia et al., NEJM 2017). Retrospective analysis showed previous RT resulted longer PFS by ICIs (Shaverdian et al., Lancet Oncol 2017). However, the optimal interval between preceding RT and ICIs has not been clarified.


Between Dec 2015 and Apr 2018, we analyzed consecutive NSCLC patients received ICIs. Patients’ characteristics, driver oncogene alteration (EGFR, ALK and ROS1), RT before ICIs (no RT, definitive or palliative thoracic radiotherapy [TRT] and palliative RT for other sites [other RT]) and PFS were investigated. The interval between the initial day of ICIs and the start date of RT (in patients with RT) or first line chemotherapy (in patients without RT) was classified as follows; within 6 months [<6], 6 to 12 months [6-12] and 12 months or longer [>12].


A total of 294 patients with NSCLC received ICIs; male / female: 186 / 108, median age: 66 (range, 32-85), squamous (Sq) / non-Sq: 60 / 234, driver oncogene alteration (positive / negative or unknown): 47 / 247, regimen (nivolumab / pembrolizumab): 235 / 59, RT (no RT / TRT / other RT): 131 / 83 / 80 and interval time categories (<6 / 6-12 / >12): 91 / 74 / 129. Significantly better PFS of ICIs was demonstrated in patients after TRT (HR 0.71, 95% CI: 0.52-0.97). According to the interval time from preceding RT, efficacy of ICIs was especially enhanced with 6-12 month interval from TRT, even after adjusting by PS, sex, age, histology, tobacco history, ICI regimen and driver oncogene status (adjusted HR 0.37, 95% CI: 0.18-0.76).


Efficacy of ICIs was significantly better in patients after TRT especially between 6 to 12 months from preceding RT.

Clinical trial identification

Legal entity responsible for the study

The authors.


Has not received any funding.

Editorial Acknowledgement


H. Horinouchi: Research funding: Ono, MSD, Merck Serono, Novartis, Chugai, Astellas, Daiichi-Sankyo and Genomic Health. Y. Goto: Research funding: MSD, BMS, Chugai. S. Kanda: Consulting or advisory role: AstraZeneca Speaker’s bureau: AstraZeneca, Bristol Myers Squibb, Chugai, Ono Pharmaceutical Research Funding: Abbvie, AstraZeneca, Bristol Myers Squibb, Ono Pharmaceutical. Y. Fujiwara: Grants and personal fees: BMS, MSD, AstraZeneca, Grants: Abbvie, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Incyte, Merck Serono, Novartis; Personal fees from Taiho, personal fees outside the submitted work: ONO. N. Yamamoto: Research grants: Quintiles, Astellas, Chugai, Esai, Taiho, BMS, Pfizer, Novartis, Daiichi-Sankyo, Bayer, Boehringer Ingelheim, Kyowa-Hakko Kirin, Takeda, ONO; Advisory role: Eisai, Takeda, OncoTherapy Science, Otsuka, Boehringer Ingelheim; Honoraria: BMS, Pfizer, AstraZeneca, Eli Lilly, ONO, Chugai. Y. Nakayama: Advisory board: AstraZeneca. Y. Ohe: Research funding: AstraZeneca, Ono Pharmaceutical, Bristol-Myers Squibb, Chugai, MSD, Novartis, Kyorin, Dainippon-Sumitomo, Lilly, Pfizer, Ignyta, Kissei; Honoraria: AstraZeneca, Ono, BMS, Chugai, MSD, Novartis, Daiichi-Sankyo, Boehringer Ingelheim, Bayer, Lilly, Pfizer. All other authors have declared no conflicts of interest.Table: 1498P

PFS of ICIs according to interval from preceding TRT or other RT in comparison with patients without RT

Total n = 294 HR [95%CI]Within 6 mo n = 91 HR [95%CI]6 to 12 mo n = 74 HR [95%CI]12 mo or longer n = 129 HR [95%CI]
No RT1111
TRT0.71 [0.52-0.97]0.98 [0.49-1.98]0.35 [0.17-0.71]0.92 [0.59-1.43]
No RT1111
Other RT1.02 [0.75-1.39]0.96 [0.56-1.66]1.22 [0.66-2.27]0.89 [0.53-1.48]

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.